Regeneron Inc. seeks to disqualify Kirkland & Ellis from representing its opponent Novartis AG in a major antitrust and ...

Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning ...

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying opportunity?

Regeneron did not bid higher on the genetic testing company because of “its assessment of 23andMe’s remaining value,” ...

Regeneron Pharmaceuticals (NASDAQ:REGN) has reportedly declined to submit a higher bid for 23andMe (OTC:MEHCQ) after a ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron ...

Lynozyfic’s global sales are projected to reach $707 million by 2031.

This was the stock's second consecutive day of losses.

Drugmaker Regeneron Pharmaceuticals will buy genetic testing firm 23andMe for $256 million through a bankruptcy auction, the ...

Detailed price information for Unitedhealth Group Inc (UNH-N) from The Globe and Mail including charting and trades.

The severe asthma treatment market is experiencing robust expansion, driven by rising disease prevalence, improved diagnostic approaches, and breakthrough therapeutic developments from key ...

Biotechnology company Regeneron will acquire 23andMe out of bankruptcy for $256 million, with a plan to keep the DNA-testing company running without interruption and uphold its privacy-protection ...